MIRM
Mirum Pharmaceuticals Inc

1,602
Loading...
Loading...
News
all
press releases
Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings?
MIRM's Livmarli remains its dominant growth engine and is expected to have boosted its top line in the third quarter.
Zacks·5d ago
News Placeholder
More News
News Placeholder
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on October 10, 2025, the Compensation Committee of Mirums Board of Directors granted inducement awards consisting of non-qualified...
Business Wire·8d ago
News Placeholder
CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?
CorMedix and Mirum Pharmaceuticals are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.
Zacks·26d ago
News Placeholder
MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
Mirum surges after second-quarter earnings and revenues top estimates, driven by Livmarli growth and a raised 2025 outlook.
Zacks·2mo ago
News Placeholder
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of +61.29% and +17.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -10.92% and +34.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·3mo ago
News Placeholder
Mirum Gains 35% in 3 Months: How Should You Play the Stock?
MIRM jumps 35% in 3 months, driven by soaring Livmarli sales and rising demand for its bile acid products.
Zacks·3mo ago
News Placeholder
Why Is Editas (EDIT) Up 40% Since Last Earnings Report?
Zacks·4mo ago
News Placeholder
Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report?
Zacks·4mo ago

Latest MIRM News

View

Advertisement|Remove ads.

Advertisement|Remove ads.